Fosbretabulin for the treatment of anaplastic thyroid cancer.
Future Oncol
; 10(13): 2015-21, 2014 Oct.
Article
in En
| MEDLINE
| ID: mdl-25396774
ABSTRACT
Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Stilbenes
/
Thyroid Carcinoma, Anaplastic
/
Antineoplastic Agents, Phytogenic
Limits:
Animals
/
Humans
Language:
En
Year:
2014
Type:
Article